In this study, progesterone is given at a specific time in the cycle. After treatment, the study follows what happens over the next part of the cycle and around the time of egg collection. The study also looks at hormone levels in the blood, including E2 (a form of estrogen), P4 (progesterone), LH (luteinizing hormone), and FSH (follicle-stimulating hormone), which are natural body signals that help control ovulation and egg development.

Participants in the study will receive either the rectal form of progesterone or a different form of luteal phase support. The study will monitor the ongoing pregnancy rate at week 12 after the embryo transfer. The trial will also look at other factors such as the levels of progesterone in the blood and urine, any side effects, and the convenience of using the rectal form of Cyclogest. The study aims to determine if the rectal administration of progesterone is as effective as other methods used in HRT-FET cycles.

The trial will continue until the end of 2026, with recruitment starting in November 2023. Participants will be monitored for various outcomes, including the rate of positive pregnancy tests, clinical pregnancies, pregnancy loss, and any complications during pregnancy, such as high blood pressure or preeclampsia. The study will help to understand the best way to support the luteal phase in women undergoing HRT-FET cycles.

The purpose of this study is to find out whether treatment with semaglutide for 12 weeks before starting fertility treatment can improve the number of good quality embryos that develop to the blastocyst stage, which is an important stage of early embryo development that occurs about five to six days after fertilization. The study will compare results between women who receive semaglutide before their fertility treatment and those who do not receive this pre-treatment.

Women in the group receiving semaglutide will take this medication for 12 weeks before beginning their fertility treatment. After this period, all women will undergo the standard fertility treatment process where their ovaries are stimulated with medications to produce multiple eggs, the eggs are collected, fertilized in the laboratory, and the resulting embryos are observed as they develop and then frozen for future use. The study will track various aspects of embryo development using time-lapse monitoring, which allows continuous observation of how embryos grow and divide. The study will also measure changes in body weight, body mass index, and markers of ovarian function before and after the semaglutide treatment period.

The treatment plan involves several medications. The main medication is Rekovelle (follitropin delta), which stimulates the ovaries to produce eggs. Other medications that may be used include Duphaston (dydrogesterone), Utrogestan (progesterone), and Ovitrelle (choriogonadotropin alfa). These medications work together to support the fertility treatment process.

During the study, participants may receive up to three treatment cycles. Each cycle involves daily injections of follitropin delta, followed by monitoring of the ovaries’ response. The treatment period for each cycle lasts about two weeks, with breaks between cycles. The medications help prepare the body for the intrauterine insemination procedure by stimulating egg development and supporting the potential pregnancy.

Participants in the study will receive one of two treatments. One group will follow a natural cycle, while the other group will receive an artificial cycle using medications. The medications involved in the artificial cycle include Progynova, which contains estradiol valerate, and Utrogestan, which contains progesterone, micronised. Progynova is taken orally as a coated tablet, and Utrogestan is used as a soft vaginal capsule. These medications help prepare the uterus for embryo transfer.

The study will compare the outcomes of these two approaches over a period of up to 12 months. Participants will be monitored for various outcomes, including the rate of clinical pregnancy, which is confirmed by detecting a fetal heartbeat. Other factors such as biochemical pregnancy rates, miscarriage rates, and live birth rates will also be observed. The study will help determine which method is more effective in supporting successful pregnancies for individuals undergoing frozen-thawed embryo transfers.

The purpose of the study is to compare two groups of women undergoing ovarian stimulation for in vitro fertilization (IVF). One group will receive a combination of clomifene citrate and 150 IU of follitropin alfa, while the other group will receive clomifene citrate and 300 IU of follitropin alfa. The study will monitor the number of good-quality blastocysts, which are early-stage embryos, according to specific criteria. Participants will receive the medications through injections or oral tablets over a period of up to 42 days, depending on the specific medication and treatment plan.

Throughout the study, various aspects of embryo development will be observed, such as the time it takes for embryos to reach different stages, including the appearance and disappearance of pronuclei (the initial stage of embryo development), division into multiple cells, and formation into a blastocyst. The study will also track the overall number of embryos and the rate at which blastocysts form. The goal is to gather information that could help improve treatment strategies for women experiencing infertility.

Participants in the study will receive either a standard formulation of micronized progesterone at a dose of 200 mg taken three times a day or a new formulation at a dose of 400 mg taken twice a day. The study will last for a period of time during which participants will be monitored for ongoing pregnancy rates, which is the main focus of the study. Other aspects being observed include the rate of embryo implantation, biochemical pregnancy rates (which are early signs of pregnancy detected through blood tests), clinical pregnancy rates (confirmed by ultrasound), and any occurrences of miscarriage. The study will also track any side effects experienced by participants.

The trial aims to provide valuable information on which formulation of micronized progesterone is more effective and better tolerated by patients undergoing fertility treatments. This information could help improve treatment options for individuals experiencing infertility. Participants will be required to attend regular appointments for blood tests and medication distribution as part of the study process.

The purpose of the study is to see if providing luteal phase support with vaginal progesterone is better than not providing any support, in terms of achieving a live birth. If it is found to be beneficial, the study will also compare whether a 7-week treatment is more effective than a 3-week treatment. Participants in the study will receive either the progesterone treatment or a placebo, and their progress will be monitored over time to assess various outcomes related to pregnancy and birth.

Throughout the study, researchers will track several outcomes, including live birth rates, pregnancy progression, and any complications that may arise during pregnancy. The study will also look at the cost-effectiveness of the treatment and measure progesterone levels in blood samples. The trial is expected to continue until early 2026, with the goal of providing valuable insights into the effectiveness of vaginal progesterone in supporting successful pregnancies for those experiencing infertility.

The purpose of the study is to compare the chances of achieving at least one good quality blastocyst, which is an early stage of embryo development, after using corifollitropin alfa versus the modified natural cycles. A blastocyst is considered good quality if it meets specific criteria known as the Gardner score. Participants in the study will receive either the medication or a placebo, and their progress will be monitored over a period of time to assess the outcomes.

Throughout the study, participants will receive injections of the medication under the skin, a method known as subcutaneous use. Other medications involved in the study include ganirelix (Orgalutran), choriogonadotropin alfa (Ovitrelle), and follitropin beta (Puregon), all of which are also solutions for injection. The study aims to provide valuable insights into the effectiveness of these treatments in improving the chances of conception for women with subfertility.

The purpose of the study is to compare the number of mature eggs retrieved using these two different methods. Participants will receive either the two doses of CFA or the combination of CFA and rFSH. The study will also look at other factors, such as the total number of eggs collected, hormone levels on the day of egg collection, and any side effects like Ovarian Hyperstimulation Syndrome (OHSS), which is a condition where the ovaries become swollen and painful. Additionally, participants will complete a quality of life questionnaire to assess their experience during the study.

The study will take place over a period of time, with participants undergoing the treatment and monitoring process. This includes receiving the medications, attending appointments for blood tests, and having the eggs collected. The goal is to determine which method is more effective in helping women preserve their fertility by producing a higher number of mature eggs.

The purpose of the study is to compare these treatments in terms of how they affect the quality of life and satisfaction of patients undergoing fertility preservation or preimplantation genetic testing (PGT). Participants will receive the treatments through subcutaneous injections, which means the medication is injected under the skin. The study will involve two cycles of treatment, and participants will be asked to complete questionnaires about their experiences and satisfaction after each cycle.

Throughout the study, participants will be monitored to assess their response to the treatments. The study aims to provide insights into which method may offer better outcomes for individuals seeking fertility treatments. The information gathered will help improve understanding of how these treatments impact patients’ lives and may guide future approaches to managing subfertility.

The purpose of the study is to determine if adding progesterone support during a specific phase of the menstrual cycle, known as the luteal phase, can increase the chances of a live birth for couples undergoing a fertility treatment called intra-uterine insemination (IUI) with mild ovarian stimulation. This involves using a medication called FSH to gently stimulate the ovaries. The study will follow participants over a period of six months to observe outcomes such as pregnancy rates, live births, and any side effects experienced during the treatment.

Participants in the study will be monitored for various outcomes, including the number of IUI cycles they undergo, any pregnancies that occur, and the overall impact on their quality of life. The study will also assess the cost-effectiveness of adding progesterone support to the treatment. The findings from this study aim to provide valuable insights into improving fertility treatment outcomes for couples facing unexplained infertility.

Participants in the study will receive treatment over a period of time, with the maximum treatment period for Cyclogest being 10 days and for Estrofem being 16 days. The study aims to determine if the rectal administration of progesterone is as effective as the traditional vaginal method in supporting pregnancy during these cycles. The study will also look at the optimal levels of progesterone in the blood after rectal administration and assess various outcomes such as ongoing pregnancy rates at 12 weeks, positive pregnancy tests, and any side effects or complications during pregnancy.

Throughout the study, participants will be monitored for different outcomes, including the rate of ongoing pregnancies, clinical pregnancies, and any pregnancy losses. The study will also evaluate the convenience and any side effects of using Cyclogest rectally. By the end of the study, researchers hope to gather valuable information on the effectiveness and safety of this treatment approach for individuals undergoing HRT-FET cycles.

The purpose of the study is to explore whether there are differences in various health aspects of the mother and baby when using different methods of frozen embryo transfer. The study will look at how the presence of the corpus luteum—a temporary structure in the ovaries that produces hormones—affects pregnancies achieved through frozen embryo transfer. Researchers will examine factors such as the function of blood vessels and the placenta, the mother’s heart health, and the growth and development of the fetus.

Participants in the study will receive one of the medications mentioned above, or a placebo, and will be monitored throughout their pregnancy. The study will assess various health indicators, including hormone levels and heart function, to understand the impact of the treatments. The study is expected to continue until 2027, with recruitment starting in 2024.

The purpose of the study is to see if using cpFT can increase the rate of live births in women under 37 years of age who are undergoing their first embryo transfer. During the study, participants will undergo the standard ICSI procedure, but with the addition of cpFT to the culture medium. The study will last for a maximum of six days, during which the development of the eggs and embryos will be closely monitored. The study will compare the outcomes of those who receive the cpFT treatment with those who do not, to determine if there is a significant improvement in live birth rates.

Participants in the study will not receive the cpFT solution directly, as it is only used in the laboratory setting. The study will also look at various factors related to embryo development, such as the number of mature eggs, the quality of embryos, and the rate of successful pregnancies. The ultimate goal is to find a way to help more couples achieve a successful pregnancy and have a healthy baby through the use of this innovative treatment.